Cited by 1,685T-cell and B-cell ImmunologyImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

CTLA-4 is a second receptor for the B cell activation antigen B7.

Open access

Linsley, P S, Brady, W, Urnes, M, Grosmaire, L S, Damle, N K, Ledbetter, J A·1991·The Journal of experimental medicine

Open this paper in CoChat — free account Open PDF

Abstract

Functional interactions between T and B lymphocytes are necessary for optimal activation of an immune response. Recently, the T lymphocyte receptor CD28 was shown to bind the B7 counter-receptor on activated B lymphocytes, and subsequently to costimulate interleukin 2 production and T cell proliferation. CTLA-4 is a predicted membrane receptor from cytotoxic T cells that is homologous to CD28 and whose gene maps to the same chromosomal band as the gene for CD28. It is not known, however, if CD28 and CTLA-4 also share functional properties. To investigate functional properties of CTLA-4, we have produced a soluble genetic fusion between the extracellular domain of CTLA-4 and an immunoglobulin C gamma chain. Here, we show that the fusion protein encoded by this construct, CTLA4Ig, bound specifically to B7-transfected Chinese hamster ovary cells and to lymphoblastoid cells. CTLA4Ig also immunoprecipitated B7 from cell surface 125I-labeled extracts of these cells. The avidity of 125I-labeled B7Ig fusion protein for immobilized CTLA4Ig was estimated (Kd approximately 12 nM). Finally, we show that CTLA4Ig was a potent inhibitor of in vitro immune responses dependent upon cellular interactions between T and B lymphocytes. These findings provide direct evidence that, like its structural homologue CD28, CTLA-4 is able to bind the B7 counter-receptor on activated B cells. Lymphocyte interactions involving the B7 counter-receptor are functionally important for alloantigen responses in vitro.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.174.3.561

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia
Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A., & Arnheim, N. (1985) · Science · doi:10.1126/science.2999980 · Cited by 8,956
Adhesion receptors of the immune system
Springer, T. A. (1990) · Nature · doi:10.1038/346425a0 · Cited by 6,477
Approaching the asymptote? Evolution and revolution in immunology.Preprint
Janeway, C. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,396
The Immunoglobulin Superfamily: Domains For Cell Surface Recognition
Williams, A., & Barclay, A. N. (1988) · Annual Review of Immunology · doi:10.1146/annurev.iy.06.040188.002121 · Cited by 2,270
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
A Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.
Linsley, P. S., Brady, W., Grosmaire, L. S., Aruffo, A. A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.721 · Cited by 1,126
Self-citation
Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G. C. L., & Thompson, C. B. (1989) · Science · doi:10.1126/science.2540528 · Cited by 866
Self-citation
Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.
Aruffo, A. A., & Seed, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8573 · Cited by 787

Flagged first, then by citations

Show all 41 references

Sorted by citations

Items 801–900 of 1,000

CTLA4 Silencing with siRNA Promotes Deviation of Th1/Th2 in Chronic Hepatitis B Patients
Yu, Y., Wu, H., Tang, Z., & Zang, G. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.17 · Cited by 29
“Previous studies have demonstrated that blockage of signaling transduction between CD28 and CTLA4-Ig inhibited the response of T cells and prolonged the allograft survival in several rodent and organ transplantation models (4-7).”
CD86 Stimulation on a B Cell Activates the Phosphatidylinositol 3-Kinase/Akt and Phospholipase Cγ2/Protein Kinase Cαβ Signaling Pathways
Kin, N. W., & Sanders, V. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6727 · Cited by 30
“Collectively, these findings suggest that B cells and T cells express costimulatory molecules during different phases of an immune response that possibly mediate opposing effector functions, with CD28/CD86 involved in immune enhancement and CTLA-4/CD80 involved in immune suppression.”
Background
T-cell activation and transplantation tolerance
Priyadharshini, B., Greiner, D. L., & Brehm, M. A. (2011) · Transplantation Reviews · doi:10.1016/j.trre.2011.09.002 · Cited by 30
“After the discovery of CD28, cytotoxic T lymphocyte antigen-4 (CD152) was identified based on structural homology to CD28, and a functional role for this molecule was suggested by the ability of a CD152immunoglobulin (Ig) fusion protein to inhibit T-cell activation [35].”
Background
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
Laheru, D. A., Pardoll, D. M., & Jaffee, E. M. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0151 · Cited by 30
An efficient homologous recombination vector pTV(I) contains a hot spot for increased recombinant protein expression in Chinese hamster ovary cells
Koduri, R. K., Miller, J. T., & Thammana, P. (2001) · Gene · doi:10.1016/s0378-1119(01)00772-7 · Cited by 30
CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals
Köchli, C., Wendland, T., Frutig, K., Grunow, R., Merlin, S., & Pichler, W. J. (1999) · Immunology Letters · doi:10.1016/s0165-2478(98)00107-2 · Cited by 31
Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation
Gool, S. V., Ceuppens, J. L., Walter, H., & de Boer, M. (1994) · Blood · doi:10.1182/blood.v83.1.176.176 · Cited by 30
A Role for CTLA‐4‐Mediated Inhibitory Signals in Peripheral T Cell Tolerance?
Allison, J. P., Chambers, C. A., Hurwitz, A. A., Sullivan, T., Boitel, B., Fournier, S., Brunner-Weinzierl, M. C., & Krummel, M. F. (2007) · Novartis Foundation symposium · doi:10.1002/9780470515525.ch7 · Cited by 30
Intracerebral xenotransplantation: recent findings and perspectives for local immunosuppression
Lévêque, X. T., Cozzi, E., Naveilhan, P., & Neveu, I. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834494b5 · Cited by 29
Murine regulatory T cells induce death of effector T, B, and NK lymphocytes through a contact-independent mechanism involving telomerase suppression and telomere-associated senescence
Zhdanov, D. D., Gladilina, Y. A., Pokrovsky, V. S., Grishin, D. V., Grachev, V. A., Orlova, V. S., Pokrovskaya, M. V., Alexandrova, S. S., & Sokolov, N. N. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.06.008 · Cited by 29
Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance
Harigai, M., Ishiguro, N., Inokuma, S., Mimori, T., Ryu, J., Takei, S., Takeuchi, T., Tanaka, Y., Takasaki, Y., Yamanaka, H., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1524998 · Cited by 29
“In contrast, in the adalimumab PMS that began in 2008 [18], as well as the ABA PMS that began in 2010 [9], the proportion of patients aged between 60 and 69 years was the highest compared Figure 3.”
Result
Expression of major histocompatibility complex class II antigen in neoplastic cells of canine cutaneous histiocytoma
Kipar, A., Baumgärtner, W., Kremmer, E., Frese, K., & Weiss, E. (1998) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(97)00170-0 · Cited by 29
Regulatory T-cell dynamics with abatacept treatment in rheumatoid arthritis
Langdon, K., & Haleagrahara, N. (2018) · International Reviews of Immunology · doi:10.1080/08830185.2018.1465943 · Cited by 30
T cell costimulatory pathways: blockade for autoimmunity
Najafian, N., & Khoury, S. J. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.2.227 · Cited by 29
“T cells also express CTLA-4, a molecule that is highly homologous to CD28, which also binds CD80 and CD86 [10].”
BackgroundInfluential
Afferent lymph veiled cells stimulate proliferative responses in allogeneic CD4+ and CD8+ T cells but not γδ TCR+ T cells
Howard, C. J., Sopp, P., Brownlie, J., Parsons, K. R., Kwong, L. S., & Collins, R. A. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-680.x · Cited by 29
Production of Monoclonal Antibodies Using a Secretion Capture Report Web
Kenney, J. S., Gray, F., Ancel, M.-H., & Dunne, J. F. (1995) · Nature Biotechnology · doi:10.1038/nbt0895-787 · Cited by 29
New Insights into the Functionality of a Virion-Anchored Host Cell Membrane Protein: CD28 Versus HIV Type 1
Giguère, J.-F., Paquette, J., Bounou, S., Cantin, R., & Tremblay, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2762 · Cited by 29
“The use of RAJI cells to capture such progeny viruses showed that the binding of 92HT599 and 93UG070 to these cells is partly mediated through an interaction between CD28 and B7-1/B7-2 because treatment with CTLA-4Ig diminishes the amounts of viruses attached to the cell surface (Fig.”
BackgroundInfluential
Pancreatic Islet Transplantation
Gill, R. G. (1994) · Humana Press eBooks · doi:10.1007/978-1-4612-0241-7_3 · Cited by 31
Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand‐dependent mechanism: CTLA4‐Ig protects Vβ8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B
Lane, P. J. L., Haller, C., & McConnell, F. M. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260420 · Cited by 29
Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains
Lipoldová, M., Kosařová, M., Zajı́cová, A., Holáň, V., Hart, A. A. M., Krulová, M., & Démant, P. (1995) · Immunogenetics · doi:10.1007/bf00172155 · Cited by 29
Novel therapeutics for the treatment of graft-versus-host disease
Jacobsohn, D. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.9.1271 · Cited by 29
“CTLA-4 Ig binds to B7 molecules with high affinity and blocks signal 2 by preventing the binding of B7 on the APC to CD28 on the T cell [28].”
Background
Tolerance Induction as a Therapeutic Strategy for the Control of Autoimmune Endocrine Disease in Mouse Models
Parish, N. M., Hutchings, P. R., O'REILLY, L., Quartey‐Papafio, R., Healey, D. G., Ozegbe, P., & Cooke, A. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00073.x · Cited by 29
Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives
Qiao, D., Wang, R. C., & Wang, Z. (2025) · Cells · doi:10.3390/cells14221804 · Cited by 39
Immuno-modulatory activity of Ganoderma lucidum-derived polysacharide on human monocytoid dendritic cells pulsed with Der p 1 allergen
Jan, R., Lin, T., Hsu, Y., Lee, S., Lo, S., Chang, M., Chen, L., & Lin, Y. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-31 · Cited by 28
“T-cell proliferation requires at least two signals, one through contact of antigenMHC with T cell receptors and the other through an interaction between co-stimulatory molecules [40,41].”
Two Regions in the CD80 Cytoplasmic Tail Regulate CD80 Redistribution and T Cell Costimulation
Doty, R. T., & Clark, E. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2700 · Cited by 28
Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis
Chitale, S., & Moots, R. J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.115 · Cited by 28
“2 Drug interactions The clearance of abatacept was not altered with concomitant use of DMARDs, NSAIDs or anti-TNF agents [20] ; however, the concomitant use of biologic agents with abatacept increased the risk of infections without increasing efficacy and hence is not recommended [23,30] .”
BackgroundInfluential
Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes
Miller, R. E., Fayen, J. D., Mohammad, S. F., Stein, K. R., Kadereit, S., Daum‐Woods, K., Sramkoski, R. M., Jacobberger, J. W., Templeton, D. J., Shurin, S. B., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00831-7 · Cited by 28
“CTLA-4, which is expressed exclusively on activated T cells, binds both B7-1 and B7-2 with a 10-fold to 20-fold higher affinity [17–19], thereby competing with CD28 for its activating ligand.”
Background
Antigen presentation in virus infection
Murray, N., & McMichael, A. J. (1992) · Current Opinion in Immunology · doi:10.1016/s0952-7915(06)80030-0 · Cited by 28
Accumulation of CTLA‐4 expressing T lymphocytes in the germinal centres of human lymphoid tissues‘pa
CASTAN, J., Tenner‐Racz, K., Rácz, P., Fleischer, B., & Bröker, B. M. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00162.x · Cited by 28
A chicken homologue of the co-stimulating molecule CD80 which binds to mammalian CTLA-4
O'Regan, M. N., Parsons, K. R., Tregaskes, C. A., & Young, J. R. (1999) · Immunogenetics · doi:10.1007/s002510050464 · Cited by 28
T cell receptor stimulation, but not CD28 costimulation, is dependent on LFA‐1‐mediated events
Green, J. M., Zheng, X., Shimizu, Y., Thompson, C. B., & Turka, L. A. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240141 · Cited by 28
T cell mediated immunotherapy for B cell lymphoma
Schultze, J. L., & Nadler, L. M. (1999) · Journal of Molecular Medicine · doi:10.1007/s001090050358 · Cited by 28
“CTLA-4 [72] is a second receptor for the B7 family members on T cells [73].”
Background
Costimulation in Tolerance and Autoimmunity
Guerder, S., & Flavell, R. A. (1995) · International Reviews of Immunology · doi:10.3109/08830189509061743 · Cited by 28
Expression of CTLA-4 Molecule in Peripheral Blood T Lymphocytes from Patients with Systemic Lupus Erythematosus
Liu, M. F., Liu, H., Wang, C., & Lei, H. (1998) · Journal of Clinical Immunology · doi:10.1023/a:1023226621966 · Cited by 28
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Martineau, R., Susini, S., & Marabelle, A. (2024) · Immunological Reviews · doi:10.1111/imr.13427 · Cited by 27
T-cell co-stimulatory blockade in transplantation: two steps forward one step back!
Riella, L. V., & Sayegh, M. H. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.845661 · Cited by 28
“2) as CD28, though with greater affinity [32].”
BackgroundInfluential
Immune suppression in cynomolgus monkeys by XPro9523
Bernett, M. J., Chu, S. Y., Leung, I., Moore, G. L., Lee, S., Pong, E., Chen, H., Phung, S., Muchhal, U. S., Horton, H. M., et al. (2013) · mAbs · doi:10.4161/mabs.23976 · Cited by 27
Biological Therapies for Rheumatoid Arthritis: Progress to Date
Malviya, G., Salemi, S., Laganà, B., Diamanti, A. P., D’Amelio, R., & Signore, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0021-x · Cited by 27
“Mechanism of action The role of activated T cell in the synovium of RA patients is well described [99, 100]; T cells require two distinct signals for full activation.”
Background
Encapsulated piscine (tilapia) islets for diabetes therapy: studies in diabetic NOD and NOD ‐SCID mice
Safley, S. A., Cui, H., Cauffiel, S. M. D., Xu, B., Wright, J. R., & Weber, C. J. (2014) · Xenotransplantation · doi:10.1111/xen.12086 · Cited by 28
“The activation of T cells to proliferate and secrete cytokines and chemokines depends upon interactions between the T-cell receptor with MHC–peptide complexes on antigen presenting cells (APCs) and with costimulatory signals provided by interactions such as CD28 and CD154 on the T cells with CD80/ CD86 and CD40, respe…”
Background
Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade
Kanda, Y., Okazaki, T., & Katakai, T. (2021) · Cancers · doi:10.3390/cancers13184616 · Cited by 30
“CTLA-4 is a structural homolog of CD28, and a typical inhibitory receptor that is expressed on activated T cells and regulatory T cells (Tregs) [77,78].”
Background
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies
Preddy, I., Nandoliya, K. R., Miska, J. M., & Ahmed, A. U. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.012 · Cited by 27
Therapeutic Approaches to Multiple Sclerosis
Ulzheimer, J. C., Meuth, S. G., Bittner, S., Kleinschnitz, C., Kieseier, B. C., & Wiendl, H. (2010) · BioDrugs · doi:10.2165/11537160-000000000-00000 · Cited by 27
“The B7/CD28-CTLA4 pathway can be modulated by CTLA4-Ig, a chimeric protein consisting of the extracellular domain of human CTLA4 fused to the Fc region of human IgG-1.”
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools
Singh, S., Meyering, M., Ramwadhdoebé, T. H., Stynenbosch, L. F. M., Redeker, A., Kuppen, P. J. K., Melief, C. J. M., Welters, M. J. P., & van der Burg, S. H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1251-3 · Cited by 27
“In addition to an enhanced cross-priming [25], IFNalso upregulates the co-stimulatory molecule CD80 on monocytes, a molecule essential for T-cell activation [34, 35].”
Background
Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award
Hurst, J. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci84236 · Cited by 27
“In 1991, Peter Linsley and colleagues found an additional molecule on T cells, CTLA-4, that binds B7 molecules (20, 21), but researchers in the field were puzzled about its function, particularly because CTLA-4’s avidity for B7 was so much higher than that of CD28 (22).”
Prevention of Acute Lung Allograft Rejection in Rat by CTLA4Ig
Shiraishi, T., Yasunami, Y., Takehara, M., Uede, T., Kawahara, K., & Shirakusa, T. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.20306.x · Cited by 27
“Interaction of CD28 with B7 molecules provides a second ‘positive’ signal that results in T-cell activation.”
BackgroundInfluential
Tolerance and the “Holy Grail” of transplantation
Schroeder, R. A., Marroquin, C. E., & Kuo, P. C. (2003) · Journal of Surgical Research · doi:10.1016/s0022-4804(03)00081-7 · Cited by 27
“The fusion protein CTLA4-Ig blocks co-stimulation via CD28 by binding to B& on APCs and has been demonstrated to significantly prolong kidney, heart and islet allograft survival in rodents [2, 47, 48].”
Background
Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade
Schaub, M., Stadlbauer, T. H. W., Chandraker, A. K., Vella, J. P., Turka, L. A., & Sayegh, M. H. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v95891 · Cited by 27
Signal Transduction by the Antigen Receptors of B and T Lymphocytes
Gold, M. R., & Matsuuchi, L. (1995) · International review of cytology · doi:10.1016/s0074-7696(08)62159-2 · Cited by 27
Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells
Gause, W. C., Urban, J. F., Linsley, P. S., & Lu, P. (1995) · Immunologic Research · doi:10.1007/bf02918215 · Cited by 27
Self-citation
Development of Human T-Cell Leukemia Virus Type 1-Transformed Tumors in Rats following Suppression of T-Cell Immunity by CD80 and CD86 Blockade
Hanabuchi, S., Ohashi, T., Koya, Y., Kato, H., Takemura, F., Hirokawa, K., Yoshiki, T., Yagita∥, H., Okumura, K., & Kannagi, M. (2000) · Journal of Virology · doi:10.1128/jvi.74.1.428-435.2000 · Cited by 27
“These molecules provide a critical costimulatory signal for T-cell immune responses via their interaction with CD28 on T cells (2, 8, 9, 12, 17, 21, 24 , 26, 45).”
Background
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome
Krishnamurthy, N., Nishizaki, D., Lippman, S. M., Miyashita, H., Nesline, M., Pabla, S., Conroy, J. M., DePietro, P., Kato, S., & Kurzrock, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220510 · Cited by 28
The delicate balance of melanoma immunotherapy
Gyorki, D. E., Callahan, M. K., Wolchok, J. D., & Ariyan, C. E. (2013) · Clinical & Translational Immunology · doi:10.1038/cti.2013.5 · Cited by 26
Mechanisms of T-cell inhibition: implications for cancer immunotherapy
Mittendorf, E. A., & Sharma, P. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.144 · Cited by 26
The immunological synapse as a pharmacological target
Finetti, F., & Baldari, C. T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.009 · Cited by 28
Evolution of Molecular Targets in Melanoma Treatment
Tran, K. B., Buchanan, C. M., & Shepherd, P. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200130091318 · Cited by 26
B Cell Aberrance in Lupus: the Ringleader and the Solution
Nie, Y., Zhao, L., & Zhang, X. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08820-7 · Cited by 26
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
Surfactant Protein D-Mediated Decrease of Allergen-Induced Inflammation Is Dependent upon CTLA4
Lin, K., Jen, K. Y., Suarez, C. J., Crouch, E. C., Perkins, D. L., & Finn, P. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901947 · Cited by 26
“Activated T cells express negative regulators including CTLA4 (14).”
Background
Combined use of insulin and endothelin-1 causes decrease of protein expression of ?-subunit of insulin receptor, insulin receptor substrate-1, and insulin-stimulated glucose uptake in rat adipocytes
Shih, K., Kwok, C., & Ho, L.-T. (2000) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(20000801)78:2 · Cited by 13
Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model
Yap, X. Z., McCall, M. B. B., & Sauerwein, R. W. (2019) · Immunological Reviews · doi:10.1111/imr.12811 · Cited by 27
Immunosuppression for lung transplantation
Choo, Y. N. (2009) · Frontiers in bioscience · doi:10.2741/3330 · Cited by 27
Anergy induction in encephalitogenic T cells by brain microvessel endothelial cells is inhibited by interleukin‐1
Bourdoulous, S., Béraud, E., Page, C. L., Zamora, A. J., Ferry, A., Bernard, D., Strosberg, A. D., & Couraud, P. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250507 · Cited by 26
Blocking Costimulatory Signals to Induce Transplantation Tolerance and Prevent Autoimmune Disease
Khoury, S. J., Sayegh, M. H., & Turka, L. A. (1999) · International Reviews of Immunology · doi:10.3109/08830189909043024 · Cited by 26
The Antigen-Presenting Cell Function of Reed-Sternberg Cells
Delabie, J., Chan, W. C., Weisenburger, D. D., & Wolf‐Peeters, C. D. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509064920 · Cited by 26
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4-IMMUNOGLOBULIN FUSION PROTEIN COMBINED WITH METHOTREXATE/CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PREVENTION IN A CANINE DOG LEUKOCYTE ANTIGEN-NONIDENTICAL MARROW TRANSPLANT MODEL1
Yu, C., Linsley, P. S., Seidel, K. D., Sale, G., Deeg, H. J., Nash, R. A., & Storb, R. F. (2000) · Transplantation · doi:10.1097/00007890-200002150-00027 · Cited by 26
Self-citation
Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients1
Pistillo, M. P., Tazzari, P. L., Bonifazi, F., Bandini, G., Kato, T., Matsui, T., Nishioka, K., Conte, R., & Ferrara, G. B. (2002) · Transplantation · doi:10.1097/00007890-200204270-00019 · Cited by 26
“It is interesting that T cells also express the costimulatory molecule CTLA-4 (CD152), a structural homologue of CD28, which is rapidly induced after T-cell activation and binds to the B7 family of molecules but with a much higher affinity than CD28 (8, 9, 10).”
Background
Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen.
He, X.-S., Chen, H. S., Chu, K., Rivkina, M., & Robinson, W. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7274 · Cited by 26
Alloantigen presentation by B cells: analysis of the requirement for B-cell activation.
Wilson, J. L., Cunningham, A. C., & Kirby, J. A. (1995) · PubMed Central · Cited by 26
Expression and function of the costimulatory molecule B7 on murine Langerhans cells: Evidence for an alternative CTLA‐4 ligand
Razi-Wolf, Z., Falo, L. D., & Reiser, H. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240405 · Cited by 26
Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises
Bandini, S., Ulivi, P., & Rossi, T. (2024) · Cells · doi:10.3390/cells13040337 · Cited by 27
“This interaction induces negative signals to T cells, and drives to attenuation of T cell proliferation, activation, and overall function [36,37].”
Background
A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
Xu, L., Chen, Y., Xiong, L., Shen, Y., Zhou, Z., Wang, S., & Xu, X. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2512645 · Cited by 32
“9,10 The extracellular role of CTLA-4 is equally significant, as CTLA-4 can capture its ligands from opposing cells via trans-endocytosis and degrade them intracellularly, resulting in impaired co-stimulation through CD28.”
Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Trimarchi, H. (2015) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1872214809666150302104542 · Cited by 25
Immunotherapy of melanoma
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 26
“It is Please cite this article in press as: Kee D, McArthur G, Immunotherapy j.ejso.2016.07.014 expressed on the surface of activated T cells, where it competes with the co-stimulatory CD28 receptor for their shared ligand, B7.”
Influential
Immunotherapy a New Hope for Cancer Treatment: A Review
Rouz, F. N., Shirkhoda, M., Memari, F., Dana, H., Chalbatani, G. M., Mahmoodzad, H., Samarghand, N., Gharagozlo, E., Mohammadi, M. H., Maleki, A. R., et al. (2018) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2018.135.150 · Cited by 25
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
Yusof, M. N. M., Chew, K. T., Kampan, N. C., & Shafiee, M. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015233 · Cited by 25
“CTLA-4 competes with CD28 for B7 ligands, thereby dampening the costimulatory signalling of the CD28/B7 axis (the second signal) [61–63].”
Background
Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Immunotherapy · doi:10.2217/imt.10.57 · Cited by 25
Immune interventions to preserve β cell function in type 1 diabetes
Ehlers, M. R. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000227 · Cited by 28
“29 Further work has uncovered an array of both co-stimulatory and co-inhibitory pathways, 30,31 many of which are amenable to pharmacologic intervention.”
Modulation of experimental blood stage malaria through blockade of the B7/CD28 T‐cell costimulatory pathway
Taylor-Robinson, & Smith (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00718.x · Cited by 25
Effect of CD80 and CD86 on T Cell Cytokine Production
Petro, T. M., Chen, S.-S. A., & Panther, R. B. (1995) · Immunological Investigations · doi:10.3109/08820139509060721 · Cited by 25
B7-1 expression by a non-antigen presenting cell-derived tumor.
Antonia, S. J., Muñoz-Antonia, T., Soldevila, G., Miller, J., & Flavell, R. A. (1995) · PubMed · Cited by 25
Modulation of Murine Lyme Borreliosis by Interruption of the B7/CD28 T-Cell Costimulatory Pathway
Shanafelt, M.-C., Kang, I., Barthold, S. W., & Bockenstedt, L. K. (1998) · Infection and Immunity · doi:10.1128/iai.66.1.266-271.1998 · Cited by 25
Expression of costimulatory CD80/CD86‐CD28/CD152 molecules in nasal mucosa of patients with perennial allergic rhinitis
Hattori, H., Okano, M., Yoshino, T., Akagi, T., Nakayama, E., Saito, C. H. F., Satoskar, A. R., Ogawa, T., Azuma, M., & Nishizaki, K. (2001) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2001.01021.x · Cited by 25
Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes
Brumeanu, T., Bot, A. I., Bona, C. A., Dehazya, P., Wolf, I., & Zaghouani, H. (1996) · Immunotechnology · doi:10.1016/1380-2933(96)85196-7 · Cited by 25
CTLA4IgG TREATMENT INDUCES LONG-TERM ACCEPTANCE OF RAT SMALL BOWEL ALLOGRAFTS1
Tarumi, K., Murakami, M., Yagihashi, A., Nakagawa, I., Hirata, K., & Uede, T. (1999) · Transplantation · doi:10.1097/00007890-199902270-00005 · Cited by 25
THE ROLE OF KERATINOCYTES IN THE PATHOPHYSIOLOGY OF CONTACT DERMATITIS
Gaspari, A. A. (1997) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(05)70316-7 · Cited by 25
Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7‐1 and B7‐2 and the B7 counter‐receptor CTLA‐4
Gerstmayer, B., Pessara, U., & Wels, W. S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00294-9 · Cited by 25
CTLA4IG INDUCES LONG-TERM GRAFT SURVIVAL OF ALLOGENEIC SKIN GRAFTS AND TOTALLY INHIBITS T-CELL PROLIFERATION IN LFA-1???DEFICIENT MICE
Malm, H., Corbascio, M., sterholm, C., Cowan, S. R., Larsen, C. P., Pearson, T. C., & Ekberg, H. (2002) · Transplantation · doi:10.1097/00007890-200201270-00024 · Cited by 25
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 27
“38,39 CTLA-4 was subsequently recognized to be found on regulatory (Treg) cells to sustain its suppressive activity by sequestering B7 binding, thereby abro-gating costimulatory signaling in other cytotoxic T cells.”
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure
Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 28
“Primarily, CTLA-4 works as a regulator that controls the magnitude of activation of thymocytes (76, 77).”
CTLA-4 antibodies: new directions, new combinations.
Funt, S. A., Page, D. B., Wolchok, J. D., & Postow, M. A. (2014) · PubMed · Cited by 24
Rheumatoid arthritis- What have we learned about the causing factors?
Jalil, S. F. (2016) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps/29/2/02.03.2016/3287/629-645 · Cited by 24
The Immunotherapy Revolution in Kidney Cancer Treatment
Hasanov, E., Gao, J., & Tannir, N. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000471 · Cited by 24
Long non‑coding RNAs XIST and MALAT1 hijack the PD‑L1 regulatory signaling pathway in breast cancer subtypes
Samir, A., Tawab, R., & Tayebi, H. M. E. (2021) · Oncology Letters · doi:10.3892/ol.2021.12854 · Cited by 26
“The effects of immune checkpoint inhibitors in different types of cancer have promoted the targeting of these signaling pathways in other tumors, such as BC (36).”
Background
The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment
Liu, S., Xu, J., & Wu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717042 · Cited by 24
“CTLA-4 shares homology with CD28, and these two molecules compete with each other in binding to their ligands, B7 family molecules (Linsley et al., 1991).”
Background
Abatacept in the treatment of rheumatoid arthritis
Todd, D. J., Costenbader, K. H., & Weinblatt, M. E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01289.x · Cited by 24
Blockade of CTLA-4 Decreases the Generation of Multifunctional Memory CD4+ T Cells In Vivo
Rudolph, M., Hebel, K., Miyamura, Y., Maverakis, E. M., & Brunner-Weinzierl, M. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003381 · Cited by 24
“Sorted cell fractions were restimulated in vitro with APC from C57BL/6 mice, OVA, and brefeldin A. CD4+ T cells were analyzed for intracellular CD40L expression by flow cytometry.”
BackgroundInfluential
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Tsai, K. K., & DAUD, A. I. (2015) · Drugs · doi:10.1007/s40265-015-0376-z · Cited by 24
Gene profiles of a human alveolar epithelial cell line after in vitro exposure to respiratory (non-)sensitizing chemicals: Identification of discriminating genetic markers and pathway analysis
Verstraelen, S., Nelissen, I., Hooyberghs, J., Witters, H. E., Schoeters, G. E. R., Cauwenberge, P. V., & Heuvel, R. V. D. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.11.017 · Cited by 24
Contact-independent suppressive activity of regulatory T cells is associated with telomerase inhibition, telomere shortening and target lymphocyte apoptosis
Zhdanov, D. D., Gladilina, Y. A., Grishin, D. V., Grachev, V. A., Orlova, V. S., Pokrovskaya, M. V., Alexandrova, S. S., Pokrovsky, V. S., & Sokolov, N. N. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.07.017 · Cited by 24
Targeting PD-1/PD-L1 in lung cancer: current perspectives
Rosell, R., González‐Cao, M., Karachaliou, N., Viteri, S., Espinosa, D. M., Teixidó, C., Ruiz, J. S., Molina‐Vila, M. Á., & Santarpía, M. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s55176 · Cited by 24

Authors: Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A.
Affiliations: Bristol-Myers Squibb (United States) (US)
ORCID: Linsley, P S
Venue: The Journal of experimental medicine
Publisher: Rockefeller University Press
Published: 1991-09-01
Volume: 174
Issue: 3
Pages: 561-569
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.174.3.561
PMC: PMC2118936
OpenAlex: W2087013294
Cited by: 1,685
References: 41
Citations by year: 2026: 14 · 2025: 31 · 2024: 49 · 2023: 37 · 2022: 35 · 2021: 49 · 2020: 51 · 2019: 55 · 2018: 49 · 2017: 49 · 2016: 59 · 2015: 52 · 2014: 39 · 2013: 41 · 2012: 39
FWCI: 27.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: CTLA-4, B7, CD28, T cell costimulation, B cell activation, T cell-B cell interaction, soluble receptor, interleukin-2, alloantigen response, cytotoxic T lymphocytes
MeSH terms: Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, B-Lymphocytes, Base Sequence, Cell Line, Ligands, Lymphocyte Cooperation, Lymphocyte Activation, Molecular Sequence Data, Oligonucleotides, Precipitin Tests, Receptors, Immunologic, Recombinant Fusion Proteins, T-Lymphocytes, Antigens, CD, B7-1 Antigen, Immunoconjugates, CTLA-4 Antigen, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4 is a second receptor for the B cell activation antigen B7.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks